FDA Approves Rapamune for Lymphangioleiomyomatosis

Share this content:
FDA Approves Rapamune for Lymphangioleiomyomatosis
FDA Approves Rapamune for Lymphangioleiomyomatosis

FRIDAY, May 29, 2015 (HealthDay News) -- Rapamune (sirolimus) has been approved by the U.S. Food and Drug Administration to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that mostly affects women of childbearing age.

LAM is characterized by the unusual growth of smooth-muscle cells among lung tissue. This can block normal airflow in the lungs and hinder delivery of oxygen to the rest of the body. The very rare disease affects only two to five women per million women globally, the FDA said in a news release.

The medication was first approved in 1999 to help prevent organ rejection among people aged 13 and older who had kidney transplant. It's now the first medication approved to treat LAM. The FDA said it granted the drug's maker, Philadelphia-based Pfizer, financial incentives as part of a program to encourage development of medications to treat rare conditions.

The most common side effects reported during clinical testing included mouth and lip ulcers, diarrhea, abdominal pain, nausea, sore throat, acne, and chest pain. More serious adverse effects included hypersensitivity and edema.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths